NAMS insider trading
NasdaqGM HealthcareNewAmsterdam Pharma Co N.V.: insider trade history from SEC Form 4 filings.
About NewAmsterdam Pharma Co N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Company website: www.newamsterdampharma.com
NAMS insider activity at a glance
FilingIQ tracks 200 insider transactions for NAMS in filings since Feb 21, 2024. The most recent transaction is dated Sep 30, 2026.
Across the full history, 14 open-market purchases
and 102 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on NAMS insider trades is 59.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest NAMS Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for NAMS?
- FilingIQ tracks 200 Form 4 insider transactions for NAMS (NewAmsterdam Pharma Co N.V.), covering filings from Feb 21, 2024 onwards. 12 of those are dated within the last 90 days.
- Are NAMS insiders net buyers or net sellers?
- Across the full Form 4 history for NAMS, 14 transactions (7%) were open-market purchases and 102 (51%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does NAMS insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is NAMS in?
- NewAmsterdam Pharma Co N.V. (NAMS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $4.14B.
Methodology & sources
Every NAMS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.